METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi
CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program … [Read more…]
